46 Health Companies Raise Over RMB 11 Billion in a Week, Backed by BMS, Pfizer, Sanofi and Others

Jan 20, 2025 17:08 CST Updated 17:08

Umoja Biopharma

Cancer Treatment Drug Developer

Tune Therapeutics

Epigenetic Editing Technology Developer

▎Edited by the WuXi AppTec content team

According to incomplete statistics from Innovation Radar, last week (January 13 to January 19), the global health sectorA total of 46 financing events were disclosed, with a total amount exceeding 11 billion yuan.。In terms of amount, there were 24 financings of 100 million yuan and above.According to the disclosed financing rounds, there were 16 early-stage financings (before Series B) and 17 mid-to-late stage financings (Series B and later). A total of 16 companies in the biopharmaceutical field received financing, involving drug types including gene therapy, multi-specific antibodies, cell therapy, etc.

#01

Tune Therapeutics Completes $175 Million Series B Financing

Keyword: Gene Therapy

Latest Financing:$175 million BRound

This round of investment institutions: Hevolution Foundation, New Enterprise Associates, Regeneron, Yosemite

January 13 news: Tune Therapeutics announced the completion of a $175 million Series B financing round, which will be used forAdvance the development of its epigenetic silencing drug Tune-401Tune-401 is a drug targeting chronic hepatitis B (HBV), which treats the disease by modulating gene expression rather than permanently altering the DNA structure. TUNE-401 uses lipid nanoparticles (LNP) to directly deliver RNA encoding activity and targeting HBV into hepatocytes. Inside these cells, the delivered RNA is translated into epigenetic silencing proteins, targeting the integration of hepatitis B virus DNA (intDNA) and covalently closed circular DNA (cccDNA) into the host cell’s genome. Additionally, funding will also be invested in the research and development of other gene, cell, and regenerative therapies at Tune Therapeutics. It is reported that the epigenetic silencing drugs from Tune Therapeutics are developed based on their tempo epigenetic editing platform, which enables drug delivery to cells via lipid nanoparticles.

#02

Umoja Biopharma Completes $100 Million Series C Financing

Keywords: Cancer Immunotherapy

Latest Financing:$100 Million Series C

This round of investment institutions: Double Point Ventures, ARK Investments, Alexandria Venture Investments, CaaS Capital, etc.

January 14 News: Umoja Biopharma announced the completion of a $100 million Series C financing round, co-led by Double Point Ventures and DCVC Bio. Umoja Biopharma plans to use the proceeds from the financing forPromote the R&D of CAR-T cell therapy product lines in China, including the lead program CD22 UB-VV400 in multiple oncology and autoimmune clinical studies. Umoja Biopharma is a clinical-stage company developing in vivo CAR-T cell therapies, committed to fully realizing the potential of CAR-T cells. Its VivoVec in vivo gene delivery platform enables patients' own immune systems to fight disease.

#03

Be Bio Completes $92 Million Series C Financing

Keywords: B-cell drugs

Latest Financing:$92 Million Series C

This round of investment institutions: ARCH Venture Partners, Alta Partners, RA Capital Management, Takeda Ventures, Bristol-Myers Squibb, etc.

January 15th, Be Bio announced the completion of a $92 million Series C financing round, led by Nextech. Be Bio will use this funding to...Advance the Phase 1/2 Clinical Trial of BE-101, treating patients with hemophilia B and advancing BE-102 for the treatment of hypophosphatasia into clinical trials. Both programs are built on Be Bio’s R&D platform, which creates durable, titratable, and reproducible therapies that deliver sustained and consistent levels of therapeutic proteins without preconditioning. Be Bio is delivering engineered B-cell medicines (BCMs) to improve the lives of patients with hemophilia B and other serious diseases.

#04

Normunity Completes $75 Million Series B Financing

Keyword: Tumor Immunotherapy

Latest Financing:$75 Million Series B

This round of investment institutions: ASamsara BioCapital, Taiho Ventures, YK Bioventures, Sequoia China, Sanofi Ventures, Pfizer Ventures, etc.

January 14th, Normunity completed a $75 million Series B financing round, co-led by Samsara BioCapital and Enavate Sciences, which will mainly...Advance the clinical development of its lead project NRM-823, and expand the product line to include therapeutic antibodies, bispecific antibodies, and payload-carrying biologics, with a focus on new targets related to tumor-specific immune suppression. NRM-823 is an engineered antibody that redirects T-cell attacks on cancer cells by binding to a highly specific tumor-associated target. Normunity stated that this new target is expressed in various types of solid tumors, making it a candidate for addressing refractory cancers. The company plans to initiate Phase 1 clinical trials for NRM-823 in the second half of 2025.

#05

Hinge Bio Completes $30 Million Series A Financing

Keywords: Multispecific Antibodies

Latest Financing:$30 Million Series A

This round of investment institutions: InVivium Capital, Lightswitch Capital, Point72, Ridgeback Capital

January 15th, Hinge Bio announced the completion of its Series A financing round, led by Point72. All funds from this round will be used forSupport the lead candidate drug HB2198 in entering Phase 1 clinical trials for patients with systemic lupus erythematosus, and develop other therapeutic drugs to meet highly unmet medical needs. Hinge Bio leverages its proprietary GEM-DIMER platform to design and develop therapeutics, bringing better treatment outcomes to patients with autoimmune diseases, inflammation, infectious diseases, and cancer. The GEM-DIMER technology platform can create multivalent, multispecific antibody therapeutics.These drugs can synergistically bind to targets, significantly enhancing bioactivity and unique functions. HB2198 aims to treat B-cell-mediated autoimmune diseases by targeting CD19 and CD20, as well as enhancing natural killer cell engagement. Preclinical in vivo studies have shown that this therapy depletes B cells more deeply and rapidly compared to other antibody therapies.

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media circles, but unauthorized republication or reproduction in any form by media or institutions to other platforms is strictly prohibited. For authorization to repost, please contact"Chuang Jian Hui"Contact us through the WeChat Official Account comments.

More Data Content Recommendations

Click "InSee", Sharing Chuangjianhui Health New Trends